Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or loss of muscle mass. Thediscoverywas reported in the journalNatureand could lead to a new therapy for...
While Mounjaro had already been used by some patients "off-label" for weight loss, the new FDA approval will allow the drugmaker to begin officially selling and marketing tirzepatide — branded as Zepbound — for weight loss too. Zepbound will be available for patients in the U.S. by t...
BEIJING, Nov. 29 (Xinhua) -- A 58-year-old man surnamed Li, weighing nearly 100 kg, was among the first patients in China to use Semaglutide as a prescribed medication for weight loss. Semaglutide is no stranger to Li, who has previously used it in another drug to manage his blood su...
A person using Ozempic on November 2, 2023, in Madrid, Spain. Novo Nordisk, the Danish firm that manufactures Ozempic, has reported record quarterly results, up almost 3% on the stock market. A top exchange-traded fund provider is betting on the long-ter...
Reports on a prescription drug called Redux that can be used for weight loss longer than previous anti-obesity products. Food and Drug Administration's approval of the drug on April 29, 1996; Types of patients targeted for the drug; Results of a clinical study on the drug's effectiveness....
she joined a trial the clinic was running for a new drug called Wegovy. “I wish I had known sooner that it wasn’t just a lack of willpower,” says Robillard, who is now 55. “The many dollars spent on going to weight-loss [meetings], the years of beating myself up, the years...
New Indication for Weight Loss Drug Semaglutide. AJN, American Journal of NursingAschenbrenner, Diane S. MS, RN
You won't find many hotter healthcare stocks these days than Novo Nordisk (NYSE: NVO). Shares of the big pharmaceutical company have skyrocketed by 50% so far in 2023. Those gains have been driven by one drug (semaglutide) that's marketed under two brand
Testing of the new weight loss drug is still in the so-called preclinical phase, which is based on studies with cells and on experimental animals. The next step is clinical trials with human participants. “We already know that GLP-1-based drugs can lead to weight ...
Orlistat is an internationally recognized new form of weight loss drug. Its commercial name is Sainike and first went on sale in New Zealand in 1998. Orlistat is a long-term and highly effective specific gastrointestinal lipase inhibitor, and it is insoluble in water, soluble in chloroform, ...